KR20230048238A - Composition for preventing, improving or treating metabolic syndrome comprising Carob extract - Google Patents

Abstract

The present invention relates to a composition for preventing, alleviating or treating metabolic syndromes such as obesity, diabetes, hyperlipidemia, and fatty liver, which contains a Ceratonia siliqua extract as an active ingredient as a natural extract. The composition of the present invention has one or more effects selected from a group consisting of weight loss, blood sugar reduction, blood lipid reduction, and fatty liver alleviation, thereby exhibiting effects in preventing, alleviating, or treating metabolic syndrome.

Description

Composition for preventing, improving or treating metabolic syndrome comprising Carob extract

The present invention relates to a composition for preventing, improving or treating metabolic syndrome such as obesity, diabetes, hyperlipidemia and fatty liver, comprising a natural extract as an active ingredient.

Obesity is a cause of various lethal metabolic diseases such as cardiovascular disease, hypertension, and Type II diabetes. When obese, fat cells not only store lipids as a long-term energy source, but also play a variety of roles involved in metabolism and inflammation of fat cells and non-adipocytes. They secrete adipokines to induce chronic inflammation and related metabolic diseases such as insulin resistance. In recent years, the incidence of metabolic syndrome known as Type II diabetes is increasing worldwide due to obesity due to lack of exercise along with high-calorie diet, and by 2025, the number of patients with metabolic syndrome will double, that is, approximately 300 million people. It is predicted to come close. Obesity caused by abnormal local fat accumulation, such as abdominal obesity, provides various causes that can seriously induce arterial atheropathy, such as hypertension, hyperlipidemia, blood clotting disorders, vascular inflammation, and insulin resistance accompanied by abnormal insulin secretion. Finally, it is a factor in the increased prevalence of fatal cardiovascular diseases. Excessive intake of fatty acids causes accumulation of triglyceride (TG) in various tissues, which accompanies an increase in lipolysis and at the same time causes an increase in circulating fatty acids in the blood, and induces insulin resistance in fat cells, resulting in muscle and pancreas and fat accumulation in non-adipocytes such as liver. When insulin resistance is induced in adipocytes, excess fatty acid binding and transport proteins cause increased fatty acid absorption in non-adipocytes, adversely affecting insulin-mediated glucose metabolism, especially in muscle cells, and at the same time, in pancreas, free fatty acids is exposed for a long time, a vicious cycle in which insulin secretion disorder is caused by a so-called lipotoxicity mechanism is repeated. In this case, high-concentration free fatty acids are also accumulated in the liver, resulting in resistance to insulin, and a large amount of glucose begins to be released from the liver. Accumulation of TG in hepatocytes also causes non-alcoholic fatty liver disease (NAFLD), and causes fat accumulation in liver cells mainly responsible for glucose metabolism, resulting in steatohepatitis secondary. , finally causing fibrosis by necrosis of hepatocytes. Therefore, the balance of fat synthesis and degradation in hepatocytes has been an important therapeutic target that can suppress the induction of insulin resistance and NAFLD caused by metabolic syndrome.

Currently, various metabolic syndrome treatments are being developed, and in recent years, appropriate control of oxidative stress, which has been pointed out as a major cause of diabetes and related complications along with appropriate blood sugar control, has emerged as the most important method for diabetes treatment, resulting in low side effects and low side effects. Development of more effective α-glucosidase blockers or antioxidants is being attempted.

Among them, metformin is a representative oral biguanide-based antidiabetic treatment and is well known as an AMPK activator. Metformin is the first drug used to treat overweight and obese type II diabetic patients with normal kidney function. It is known as the only drug capable of controlling the secretion of pancreatic enzyme granules and the activity of enzymes related to liver sugar metabolism. Metformin is currently known as the most prescribed diabetes treatment worldwide. Metformin is mainly used as a treatment for type II diabetes, but prescriptions for polycystic ovary syndrome and premature puberty are also increasing. On the other hand, side effects such as lactic acidosis caused by metformin are well known.

Therefore, there is a demand for the development of alternative health functional foods and pharmaceuticals derived from natural products that have low side effects and are more effective.

A number of documents are referenced throughout this specification and citations are indicated. The disclosure contents of the cited documents are incorporated herein by reference in their entirety to more clearly describe the content of the present invention and the level of the technical field to which the present invention belongs.

Republic of Korea Patent Publication No. 10-2020-0058326

The present inventors have researched to develop a natural product that has no side effects while exhibiting the effect of treating and suppressing metabolic syndrome such as obesity, diabetes, hyperlipidemia and fatty liver. As a result, carob extract has a remarkable effect in preventing, improving, and treating metabolic syndrome. By finding out, the present invention was completed.

Accordingly, an object of the present invention is to provide a composition for preventing, improving or treating metabolic syndrome comprising carob extract as an active ingredient.

Another object of the present invention is to provide a method for preparing a composition for preventing, improving or treating the metabolic syndrome.

Further objects and advantages of the present invention will become more apparent from the following detailed description, claims and drawings.

One aspect of the present invention is a composition for the prevention, improvement or treatment of at least one metabolic syndrome selected from the group consisting of obesity, diabetes, hyperlipidemia and fatty liver, comprising a carob extract as an active ingredient, It is to provide a composition that does.

Carob ( Ceratonia siliqua (L.) Taub) is a bean-shaped fruit of Ceratonia siliqua, which is native to the Mediterranean coast, and is known to be native to parts of the United States and Australia. It is known that kerob contains very high tannin, causing specific astringency, so that its edible is extremely limited.

The composition of the present invention includes carob extract as an active ingredient, and the term 'extract' used herein refers to an extraction result obtained by extracting the original material or treating the original material with an extraction solvent, or formulating (eg, powdering) the raw material. It also has a meaning including processed products.

When the extract used in the composition of the present invention is obtained by treating the raw material with an extraction solvent, various extraction solvents may be used, for example, polar solvents or non-polar solvents may be used. The polar solvent includes (i) water, (ii) alcohol (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, 2-butoxyethanol or ethylene). glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMF) and (v) dimethyl sulfoxide (DMSO), etc., and non-polar solvents include acetone, acetonitrile, ethyl acetate, methyl acetate, Alkanes, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl Ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride and THF or the like can also be used.

Preferably, the extract used in the present invention may be extracted by squeezing raw material or using any one selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixtures thereof as an extraction solvent, but this is not limited to

In addition, the term 'extract' used herein has the meaning commonly used in the art as a crude extract (crude extract) as described above, but also includes fractions obtained by further fractionation of the extract in a broad sense. That is, it includes not only extracts obtained by extracting raw materials or using the above-described extraction solvents, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method are also included in the extract of the present invention.

In addition, the extract of the present invention may be obtained by performing an additional process, such as filtration, concentration or drying, to remove the solvent, or filtration, concentration, and drying. For filtration, for example, filter paper or a vacuum filter may be used, concentration may be performed with a vacuum concentrator, and drying may be performed by spray drying or freeze drying to obtain a powdery extract.

For example, carob extract can be obtained by grinding carob raw materials, for example, carob fruit; And it can be prepared by a method comprising the step of performing an extraction process using any one selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixtures thereof as an extraction solvent.

According to one embodiment of the present invention, the carob extract prepared as above may contain apigenin, syringic acid and pinitol as active ingredients. The carob extract of the present invention contains at least one selected from the group consisting of obesity, diabetes, hyperlipidemia, and fatty liver without reducing appetite due to the inclusion of apigenin, syringic acid, and pinitol. It has been confirmed to have preventive, ameliorative or therapeutic effects on metabolic syndrome.

Preferably, the carob extract of the present invention may contain syringic acid in an amount of 40 μg/g to 200 μg/g. More specifically, the content of syringinic acid is 40 μg / g, 50 μg / g, 60 μg / g, 70 μg / g, 80 μg / g, 90 μg / g, 100 μg / g, 110 μg / g, 120 μg/g, 130 μg/g, 140 μg/g, 150 μg/g, 160 μg/g, 170 μg/g, 180 μg/g, 190 μg/g or 200 μg/g, but is limited thereto It is not, and may be included in any amount in the range of 40 μg / g to 200 μg / g.

More preferably, the carob extract of the present invention may include pinitol and syringic acid in a weight ratio of 200 to 500: 1 (pinitol: syringic acid). When the pinitol and syringin acid in the carob extract are included in the above weight ratio, they may have a synergistic effect compared to the case where they are included in other weight ratios. More specifically, the weight ratio of pinitol to syringinic acid contained in the carob extract may be, but is not limited to, 200:1, 300:1, 400:1 or 500:1, and any range in the range of 200 to 500:1 may be included in a weight ratio of

According to one embodiment, the composition of the present invention comprises the steps of grinding carob raw materials; And it can be prepared by including the step of performing an extraction process using any one selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixtures thereof as an extraction solvent.

The composition of the present invention prepared as described above has at least one effect selected from the group consisting of weight loss, blood sugar reduction, blood lipid reduction and fatty liver improvement, thereby preventing, improving or treating metabolic syndrome (metabolic syndrome). can indicate

In addition, in the case of existing natural extracts, in most cases, weight and body fat are reduced through appetite reduction, but the composition of the present invention does not cause appetite reduction, and at least one metabolism selected from the group consisting of obesity, diabetes, hyperlipidemia, and fatty liver It can show preventive, ameliorative or therapeutic effects of metabolic syndrome.

The present invention provides a pharmaceutical composition for the prevention and treatment of metabolic syndrome formulated in a pharmaceutical unit dosage form by adding a pharmaceutically acceptable carrier, excipient or diluent, including a composition containing the active ingredient. .

The term "pharmaceutically acceptable" means a non-toxic composition that is physiologically acceptable and does not inhibit the action of the active ingredient when administered to humans and does not usually cause allergic reactions such as gastrointestinal disorders and dizziness or similar reactions. says

Examples of the carrier, excipient or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose. , polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, the pharmaceutical composition may further include fillers, anti-coagulants, lubricants, wetting agents, flavoring agents, emulsifiers or preservatives.

The term "pharmaceutically effective amount" refers to an amount that exhibits a greater response than that of the negative control group, and preferably refers to an amount sufficient to exhibit the effect of preventing and/or treating metabolic syndrome.

In addition, the pharmaceutical composition of the present invention can be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The dosage form may be in the form of a powder, granule, tablet, emulsion, syrup, aerosol, soft or hard gelatin capsule, sterile injectable solution, or sterile powder.

The route of administration of the pharmaceutical composition of the present invention is not limited thereto, but may be administered orally or parenterally. Parenteral routes of administration may include, for example, various routes such as transdermal, intranasal, intraperitoneal, intramuscular, subcutaneous or intravenous routes. In addition, the pharmaceutical composition of the present invention can be administered in parallel with known compounds having preventive and/or therapeutic effects on metabolic syndrome.

In another aspect, the present invention provides a food composition comprising any one of the above compositions.

The food composition of the present invention includes processed forms of all natural materials such as food, functional food, nutritional supplement, health feed and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, carob extract itself can be prepared in the form of tea, juice and drink to be consumed, or granulated, encapsulated, or powdered to be consumed. In addition, in addition to the carob extract of the present invention, white peony, cornus officinalis, cinnamon gapi, ganoderma lucidum, dermis, chinensis, angelica, gardenia, astragalus, malt, tangerine, vitamin C, fructooligosaccharide, stevioside, purified water, maltodextrin, etc. It may be further included alone or in combination within a range that does not interfere with the purpose of the present invention, but other medicinal ingredients and / or additives that may be further included in the food composition of the present invention are not limited to the above examples.

For example, the food composition according to the present invention may include thiamin (vitamin B1), riboflavin, ascorbic acid, niacin, and vitamin B6 as water-soluble vitamins, and myristic acid, palmitic acid, stearic acid, oleic acid, It may include linoleic acid, etc., and may include glycolic acid and acetic acid as weak acid components, and 8 essential amino acids of threonine, valine, methionine, isoleucine, leucine, phenylalanine, tryptophan, and lysine as amino acids, aspartic acid, serine, glutamic acid, proline, glycine, alanine, cysteine, tyrosine, histidine, arginine, and the like.

The composition of the present invention has at least one effect selected from the group consisting of weight loss, blood sugar reduction, blood lipid reduction and fatty liver improvement, thereby exhibiting an effect of preventing, improving or treating metabolic syndrome.

Figure 1 shows a photograph of the carob extract prepared in Example (left: powder obtained after spray drying, right: before spray drying).
Figure 2 shows the results of evaluating the change in mouse weight in order to verify the anti-obesity effect.
Figure 3 shows the experimental results of changes in mouse body fat and abdominal fat to verify the anti-obesity effect.
Figure 4 shows the results of measuring cholesterol and neutral lipid excretion through mouse feces.
5 shows the results of measuring blood glucose concentration in order to evaluate the hypoglycemic effect.
Figure 6 shows the results of measuring the area where steatohepatitis occurred in mouse liver tissue (hepatic parenchyma).
Figure 7 shows the calculation of the change in fat accumulation rate when each test substance is treated in an adipocyte differentiation inhibition experiment using 3T3-L1 preadipocytes.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

Example

I. Test substance preparation and substance analysis

1. Preparation of carob extract

Carob (CR; Carob) was pulverized, and then extracted with 10 folds of 30% ethanol (ethanol:water = 30:70, V/V) as a solvent at 70°C for 6 hours. Then, it was filtered and concentrated to 20-25 brix at 60-65 ° C, dried under reduced pressure at 60-70 ° C, and then milled and sized to prepare carob extract as light yellow powders.

2. Material analysis

As a result of separating the components in the prepared carob extract using a high performance liquid chromatography method, it was confirmed that the carob extract contained apigenin, syringic acid and pinitol.

II. Efficacy evaluation

1. Animal Model Establishment

Various experimental animal models for the development of anti-obesity drugs have been developed in the past, but most of them induce severe obesity, so they are only suitable for evaluating the efficacy of drugs for obesity that have already been established, but are evaluated as inappropriate for the development of preventive or functional foods.

The present inventors have confirmed that obesity occurs in mice, which are rodents, by supplying a high fat diet (HFD). In other words, it was confirmed that HFD feeding can induce obesity similar to human obesity in ICR mice, and that an appropriate degree of obesity can be induced in the evaluation of the efficacy of functional foods, and an experimental animal model using HFD was established.

Specifically, a total of 200 6-week-old female ICR mice [OrientBio, Seungnam, Korea] were acclimatized to the laboratory environment for 7 days and then to HFD for 1 week. All experimental animals were treated according to the animal experimentation ethics standards under the prior approval of the Laboratory Animal Ethics Committee of Daegu Haany University. In the normal control group, NFD (Normal Fat Diet) was supplied in the same way.

As a test substance, the carob extract (CR) prepared above was used. The dose of the test substance was set at 200 mg/kg. To this end, the carob extract was dissolved in sterile distilled water at a concentration of 20 mg/ml, and forced orally once daily for 84 days at 10 ml/kg, which is the normal oral administration volume of mice. administered.

The dose of metformin used as a control drug was set at 250 mg/kg based on previous references. Metformin was also dissolved in sterile distilled water at a concentration of 25 mg/ml and then orally administered at a dose of 10 ml/kg (250 mg/kg) once daily for 84 days.

In the normal and HFD control groups, only sterilized distilled water was administered orally for the same period of time in the same manner instead of the test substance in order to apply the same administration and correction stress.

2. Changes in body weight and average feed intake

In order to verify the anti-obesity effect, changes in body weight were evaluated, and the experimental results are shown in FIG. 2 .

As a result of the experiment, the HFD control group showed a significant increase during the 1-week HFD adaptation period compared to the normal control group (NFD), and showed a significant increase in body weight during the 84-day test material administration period. On the other hand, when metformin 250 mg/kg (positive control group) and carob extract 200 mg/kg (test group) were administered, significant weight loss was observed compared to the HFD control group.

Mean feed intake in the HFD control group showed a change of -10.69% compared to the normal control group, but in the metformin 250 mg/kg and carob extract 200 mg/kg groups, the change was -1.53% and -0.78%, respectively, compared to the HFD control group. It was confirmed that it did not cause a decrease in appetite.

3. Confirmation of fat accumulation suppression and discharge effect

In order to verify the anti-obesity effect, the experimental results of changes in body fat and abdominal fat after an administration period of 84 days are shown in FIG. 3. As a result of the experiment, in the HFD control group, significant increases in body fat and abdominal fat accumulation were recognized compared to the normal control group, whereas in the metformin 250 mg/kg and carob extract 200 mg/kg administration group, there was a significant increase in body fat and abdominal fat accumulation compared to the HFD control group. It was found to show a decrease (Fig. 3).

In addition, in order to confirm the fat excretion effect, cholesterol and neutral lipid excretion through feces were measured during the 84-day administration period, and the average value was calculated and shown in FIG. As a result of the experiment, no significant difference was observed in fat excretion in the HFD control group compared to the normal control group (NFD), whereas significant cholesterol and neutral lipid excretion activities were observed in the metformin 250 mg/kg and carob extract 200 mg/kg administration groups. confirmed (FIG. 4).

4. Evaluation of hyperlipidemia improvement activity

In order to evaluate the hyperlipidemia-improving activity, changes in mouse blood cholesterol, neutral lipids, and LDL & HDL cholesterol contents were measured after an 84-day experimental period. Measurement values were expressed as mean ± SD for 8 mice, and the results are shown in Table 1 below.

As confirmed in Table 1, the 200 mg/kg administration group in the carob extract was confirmed to have excellent hyperlipidemia-improving activity in both blood cholesterol and neutral lipids, LDL & HDL cholesterol levels.

5. Assessment of blood glucose concentration

To evaluate the hypoglycemic effect, blood glucose concentration was measured and the results are shown in FIG. 5 . As a result of the experiment, a significant increase in blood glucose was confirmed in the HFD control group compared to the normal control group, whereas a significant improvement in blood glucose was observed in the group administered with metformin 250 mg/kg and carob extract 200 mg/kg compared to the HFD control group. It was confirmed to show improvement activity (FIG. 5).

6. Evaluation of liver protective effect

To evaluate the hepatoprotective effect, changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) contents in mouse blood were measured after the 84-day experimental period. Measurement values were expressed as mean ± SD for 8 mice, and the results are shown in Table 2 below.

Items
Groups ALT
(IU/L) ALT
(IU/L) GGT
(IU/L) NFD 68.88±16.99 36.25±11.32 3.13±1.46 HFD 206.88±17.29 157.88±17.78 13.13±1.81 Metformin 147.63±18.96 108.38±16.98 7.00±1.41 CR 159.25±12.41 119.00±14.39 9.63±1.41

7. Confirmation of fatty liver improvement activity

Nonalcoholic fatty liver disease (NAFLD), in which triglyceride (TG) is excessively accumulated in the liver, is associated with metabolic syndrome such as obesity, insulin resistance, type 2 diabetes, hypertension, and hyperlipidemia. It may also accompany liver steatohepatitis.

After the experimental period of 84 days, the mouse was sacrificed and the area where steatohepatitis occurred in the mouse liver tissue (hepatic parenchyma) was measured through a histological examination, and the results are shown in FIG. 6 . As a result of the experiment, significantly higher steatohepatitis was observed in the HFD control group than in the normal control group. On the other hand, in the group administered with 250 mg/kg of metformin and 200 mg/kg of carob extract, it was confirmed to have a fatty liver improving activity by showing significant improvement in steatohepatitis compared to the HFD control group (FIG. 6).

8. Confirmation of the effect according to the weight ratio of pinitol and syringic acid in carob extract

In order to confirm the effect according to the weight ratio of pinitol and syringic acid contained in the carob extract, the differentiation inhibitory activity of 3T3-L1 preadipocytes was measured after treatment with the test substance. As a control, metformin was used, and as an experimental substance, pinitol was added to the carob extract (CR) prepared in Example I to adjust the weight ratio of pinitol and syringin acid contained in the carob extract as shown in Table 3 below. . The treatment capacity of each test substance was equally set at 100 μg/ml.

sample processing capacity control 100 µg/ml pinitol 100 µg/ml syringic acid 100 µg/ml CR - carob extract prepared in Example I above 100 µg/ml CR (100:1) - carob extract adjusted to pinitol:syringic acid weight ratio of 100:1 100 µg/ml CR(200:1) - carob extract adjusted to a weight ratio of pinitol:syringic acid of 200:1 100 µg/ml CR(500:1) - carob extract adjusted to pinitol:syringic acid weight ratio of 500:1 100 µg/ml CR(1000:1) - carob extract adjusted to 1000:1 weight ratio of pinitol:syringic acid 100 µg/ml

Specifically, for culture and differentiation medium, Dulbecco's modified Eagle's medium high glucose (DMEM: Invitrogen, Carlsbad, CA, USA) was added with 10% calf serum and antibiotics, and cultured in a 5% CO ₂ , 37°C incubator so that the cells were confluent. After treatment with trypsin/EDTA, the cells are centrifuged (L-70, Bekman Coulter, Fullerton, CA, USA) to collect the cells and dispensed into 6 wells at a density of 3Х10 ⁵ cells/well for 48 hours at 100% confluency. After standing, DMEM contained 10% BCS, 23 mg/mL IBMX (Sigma-Aldrich, Chem. Co., St. Louis, MO, USA), 5 mg/mL insulin (Sigma-Aldrich), and 1 mM dexamethasone (Sigma-Aldrich). ) was added to the medium (MDI) to induce differentiation for 48 hours. The test substance was treated at a concentration of 100 μg/ml from the time of addition of the differentiation induction medium, and after differentiation for 9 days, the medium was removed, washed with phosphate buffered saline (PBS), and cells were fixed with 10% formaldehyde solution. . After washing again with PBS, adding Oil red O solution, dyeing at room temperature for 30 minutes, removing Oil red O solution, washing with distilled water, drying, observing using a phase contrast microscope, and staining with 100% isopropyl alcohol. Fat globules were dissolved and absorbance was measured at 510 nm. The value obtained during the treatment of the control group was set as 100%, and the fat accumulation rate measured during the treatment of each test substance was calculated, and the results are shown in FIG. 7 .

As a result of the experiment, even though the treatment amount was the same at a concentration of 100 μg / ml, a remarkably low fat accumulation rate was confirmed in the CR (200: 1) and CR (500: 1) treatment groups, and it was confirmed that there was a synergistic effect in the weight ratio ( Fig. 7).

Claims (12)

A composition for preventing, improving or treating at least one metabolic syndrome selected from the group consisting of obesity, diabetes, hyperlipidemia and fatty liver, comprising a carob extract as an active ingredient.
The composition according to claim 1, wherein the carob extract contains apigenin, syringic acid and/or pinitol as active ingredients.
The composition of claim 1, wherein the carob extract contains syringic acid in an amount of 40 μg/g to 200 μg/g.
The composition of claim 1, wherein the carob extract contains pinitol and syringic acid in a weight ratio of 200 to 500: 1 (pinitol: syringic acid).
The composition according to claim 1, wherein the carob extract is a carob fruit extract.
The composition according to claim 1, wherein the carob extract is extracted using any one selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixtures thereof as an extraction solvent.
The composition according to claim 1, wherein the composition has at least one effect selected from the group consisting of weight loss, blood sugar reduction, blood lipid reduction and fatty liver improvement.
The composition according to claim 1, wherein the composition has at least one effect selected from the group consisting of weight loss, body fat reduction, and abdominal fat reduction without causing a decrease in appetite.
9. The composition according to any one of claims 1 to 8, wherein the composition is a food composition.
9. The composition according to any one of claims 1 to 8, wherein the composition is a pharmaceutical composition.
A health functional food comprising the composition according to any one of claims 1 to 8.
Grinding carob raw materials; and
Performing an extraction process using any one selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, and mixtures thereof as an extraction solvent.
A method for producing a composition according to any one of claims 1 to 8 comprising a.

Images